Earnings Releases·Nov 9, 2026, 7:09 AM ET

Immunovant — Second Quarter 2026 Earnings Summary

Net loss narrowed to $97.2 million ($0.47/share) in Q2 2026 from $126.5 million ($0.73/share) in the prior year period, driven by a 25% reduction in R&D expenses to $85.0 million following the wind-down of batoclimab trials.
IMVT-1402 600 mg met the primary ACR20 endpoint in the D2T RA Phase 2 trial (92.5% vs. 75.6% placebo), while the 300 mg dose failed to show statistical significance; the company will not advance the asset in Sjögren's disease.
FDA discussions regarding the registrational path for IMVT-1402 in D2T RA are scheduled for late 2026, with top-line data expected for Graves' disease and myasthenia gravis in 2027 and CIDP in 2028.
Cash and cash equivalents decreased to $722.3 million as of September 30, 2026, from $902.1 million at the start of the year, providing sufficient runway for the potential commercial launch of IMVT-1402 in Graves' disease.